Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
The DOI matches its Crossref record; 220 of the 221 references it cites were found in a registry or an index.
Abstract
The first-line treatment for psychotic disorders remains antipsychotic drugs with receptor antagonist properties at D2-like dopamine receptors. However, long-term administration of antipsychotics can upregulate D2 receptors and produce receptor supersensitivity manifested by behavioral supersensitivity to dopamine stimulation in animals, and movement disorders and supersensitivity psychosis (SP) in patients. Antipsychotic-induced SP was first described as the emergence of psychotic symptoms with tardive dyskinesia (TD) and a fall in prolactin levels following drug discontinuation. In the era of first-generation antipsychotics, 4 clinical features characterized drug-induced SP: rapid relapse after drug discontinuation/dose reduction/switch of antipsychotics, tolerance to previously observed therapeutic effects, co-occurring TD, and psychotic exacerbation by life stressors. We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable risperidone, olanzapine, quetiapine, and aripiprazole). These studies show that the prevalence rates of SP remain high in schizophrenia (30%) and higher (70%) in treatment-resistant schizophrenia. We then present neurobehavioral findings on antipsychotic-induced supersensitivity to dopamine from animal studies. Next, we propose criteria for SP, which describe psychotic symptoms and co-occurring movement disorders more precisely. Detection of mild/borderline drug-induced movement disorders permits early recognition of overblockade of D2 receptors, responsible for SP and TD. Finally, we describe 3 antipsychotic withdrawal syndromes, similar to those seen with other CNS drugs, and we propose approaches to treat, potentially prevent, or temporarily manage SP.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“but concerns [13] have remained about supersensitivity psychosis [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“In the era of first-generation antipsychotics (FGAs) both supersensitivity psychosis and tardive dyskinesia were widely studied [9].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
In the citing paper
“Although not widely recognized, withdrawal symptoms can occur on the cessation of both first- and second-generation antipsychotics (FGAs and SGAs).17,20,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Upon the removal of blockade, persistently increased baseline presynaptic DSC in patients with schizophrenia may interact with elevated postsynaptic sensitivity to increase the likelihood of relapse.7,23”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [23]
In the citing paper
“Chouinard et al. [9] described withdrawal reactions due to antipsychotics dose decrease, discontinuation, or switch and concluded that acute withdrawal symptoms, rebound, and persistent post-withdrawal disorders may occur”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [9]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Social Origins of Depression: A Study of Psychiatric Disorder in Women.
Schnitzer, P. K., Brown, G. W., & Harris, T. (1980) · Contemporary Sociology · doi:10.2307/2065631 · Cited by 3,053
A permanent change in brain function resulting from daily electrical stimulation
Goddard, G. V., McIntyre, D. C., & Leech, C. K. (1969) · Experimental Neurology · doi:10.1016/0014-4886(69)90128-9 · Cited by 3,052
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561
Book Review: Measurement and Classification of Psychiatric Symptoms
Priest, R. G. (1975) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591577506800751 · Cited by 2,262
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393
G PROTEIN–COUPLED RECEPTOR KINASES
Pitcher, J. A., Freedman, N. J., & Lefkowitz, R. J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.653 · Cited by 1,361
Deficit and nondeficit forms of schizophrenia: the concept
(1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.5.578 · Cited by 1,332
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Classen, D. C. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280039031 · Cited by 1,134
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in Brain
Burt, D. R., Creese, I., & Snyder, S. H. (1977) · Science · doi:10.1126/science.847477 · Cited by 1,024
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Research Diagnoses for Tardive Dyskinesia
Kane, J. M. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290040080014 · Cited by 937
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 822
Dopamine Receptor Binding Enhancement Accompanies Lesion-Induced Behavioral Supersensitivity
Creese, I., Burt, D. R., & Snyder, S. H. (1977) · Science · doi:10.1126/science.877576 · Cited by 712
Correll, C. U., Leucht, S., & Kane, J. M. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.414 · Cited by 709
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Management of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
Shahid, M., Walker, G., Zorn, S., & Wong, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881107082944 · Cited by 493
Kapur, S., VanderSpek, S. C., Brownlee, B. A., & Nobrega, J. N. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046987 · Cited by 479
Psychotropic dose equivalence in Japan
Inada, T., & Inagaki, A. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12275 · Cited by 467
Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., Saha, A., Ali, M., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
Chouinard, G., & Margolese, H. C. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.02.013 · Cited by 416
Self-citationMiller, R. R., Olson, H. G., Amsterdam, E. A., & Mason, D. T. (1975) · New England Journal of Medicine · doi:10.1056/nejm197508282930902 · Cited by 404
Withdrawal of Cerivastatin from the World Market
Furberg, C. D., & Pitt, B. (2001) · Trials · doi:10.1186/cvm-2-5-205 · Cited by 400
Kapur, S. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.6.553 · Cited by 396
'Akinetic Depression' in Schizophrenia
Van Putten, T. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770330075006 · Cited by 386
Alcohol's effects on sleep in alcoholics.
Brower, K. J. (2001) · PubMed Central · Cited by 377
Disease-induced Changes in the Plasma Binding of Basic Drugs
Piafsky, K. M. (1980) · Clinical Pharmacokinetics · doi:10.2165/00003088-198005030-00004 · Cited by 358
Dopamine supersensitivity correlates with D2Highstates, implying many paths to psychosis
Seeman, P., Weinshenker, D., Quirion, R., Srivastava, L. K., Bhardwaj, S. K., Grandy, D. K., Premont, R. T., Sotnikova, T. D., Boksa, P., El-Ghundi, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409766102 · Cited by 352
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348
Elevated dopa decarboxylase activity in living brain of patients with psychosis
Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., & Dyve, S. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.24.11651 · Cited by 342
Psychosis pathways converge via D2High dopamine receptors
Seeman, P., Schwarz, J., Chen, J.-F., Szechtman, H., Perreault, M., McKnight, G. S., Roder, J. C., Quirion, R., Boksa, P., Srivastava, L. K., et al. (2006) · Synapse · doi:10.1002/syn.20303 · Cited by 330
Levodopa-induced psychosis: a kindling phenomenon
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.6.669 · Cited by 326
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · PubMed · Cited by 322
Silvestri, S., Seeman, M. V., Negrete, J.-C., Houle, S., Shammi, C. M., Remington, G. J., Kapur, S., Zipursky, R. B., Wilson, A. A., Christensen, B. K., et al. (2000) · Psychopharmacology · doi:10.1007/s002130000532 · Cited by 311
Targeting the dopamine D2receptor in schizophrenia
Seeman, P. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.515 · Cited by 302
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.1.16 · Cited by 301
Self-citation(2004) · PubMed · Cited by 296
Self-citationManagement of Cocaine Abuse and Dependence
Mendelson, J. H., & Mello, N. K. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341507 · Cited by 291
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Dopaminergic supersensitivity after neuroleptics: time-course and specificity
Muller, P., & Seeman, P. (1978) · Psychopharmacology · doi:10.1007/bf00429171 · Cited by 271
Samaha, A.-N., Seeman, P., Stewart, J., Rajabi, H., & Kapur, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5416-06.2007 · Cited by 262
Self-citationAkinesia: A Poorly Recognized Drug-Induced Extrapyramidal Behavioral Disorder
Rifkin, A. (1975) · Archives of General Psychiatry · doi:10.1001/archpsyc.1975.01760230138011 · Cited by 258
Seeman, P., & Tallerico, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.876 · Cited by 237
Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors
Seeman, P. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00187-x · Cited by 235
Moncrieff, J. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00787.x · Cited by 231
All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors
Seeman, P. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00162.x · Cited by 228
Neuroleptic-induced supersensitivity psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1409 · Cited by 224
Self-citationClozapine in treatment-resistant schizophrenics.
Kane, J. M., Honigfeld, G., Singer, J., & Meltzer, H. Y. (1988) · PubMed · Cited by 217
Perioperative β-blocker withdrawal and mortality in vascular surgical patients
Shammash, J. B., Trost, J. C., Gold, J. M., Berlin, J. A., Golden, M. A., & Kimmel, S. E. (2001) · American Heart Journal · doi:10.1067/mhj.2001.111547 · Cited by 212
Atypical Antipsychotics Part I: Pharmacology, Pharmacokinetics, and Efficacy
Markowitz, J. S., Brown, C. S., & Moore, T. R. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17215 · Cited by 208
de Bartolomeis, A., Tomasetti, C., & Iasevoli, F. (2015) · CNS Drugs · doi:10.1007/s40263-015-0278-3 · Cited by 204
Mechanism of propranolol withdrawal phenomena.
Nattel, S., Rangno, R. E., & Van Loon, G. (1979) · Circulation · doi:10.1161/01.cir.59.6.1158 · Cited by 202
Rebound Insomnia: A New Clinical Syndrome
Kales, A., Scharf, M. B., & Kales, J. D. (1978) · Science · doi:10.1126/science.684426 · Cited by 200
Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways
Urban, J. D., Vargas, G. A., von Zastrow, M., & Mailman, R. B. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301071 · Cited by 197
Dopamine D2 Receptors as Treatment Targets in Schizophrenia
Seeman, P. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.4.1.5 · Cited by 193
Natesan, S., Reckless, G. E., Nobrega, J. N., Fletcher, P. J., & Kapur, S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300983 · Cited by 192
Withdrawal syndromes associated with antipsychotic drugs
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1321 · Cited by 191
Five Weeks to Escape the Sleeping-pill Habit
Oswald, I., & Priest, R. G. (1965) · BMJ · doi:10.1136/bmj.2.5470.1093 · Cited by 182
Michelson, D., Fava, M., Amsterdam, J., Apter, J., Londborg, P., Tamura, R., & Tepner, R. G. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.4.363 · Cited by 181
Basic Principles of Pharmacokinetics
Benet, L. Z., & Zia-Amirhosseini, P. (1995) · Toxicologic Pathology · doi:10.1177/019262339502300203 · Cited by 179
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176
Self-citationGEORGE, S. R., WATANABE, M., PAOLO, T. D., FALARDEAU, P., LABRIE, F., & SEEMAN, P. (1985) · Endocrinology · doi:10.1210/endo-117-2-690 · Cited by 171
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
Self-citationNew Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164
Self-citationWadenberg, M.-L. G., Kapur, S., Soliman, A., Jones, C., & Vaccarino, F. (2000) · Psychopharmacology · doi:10.1007/s002130000466 · Cited by 158
Margolese, H. C., Chouinard, G., Kolivakis, T., Beauclair, L., & Miller, R. J. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000907 · Cited by 157
Self-citationMiller, R. J., & Chouinard, G. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90044-e · Cited by 150
Self-citationFactors related to tardive dyskinesia
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.1.79 · Cited by 150
Self-citationD2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.173 · Cited by 144
Bandelow, B., Chouinard, G., Bobes, J., Ahokas, A., Eggens, I., Liu, S., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990423 · Cited by 142
Self-citationSchizophrenia and dopamine receptors
Seeman, P. M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.06.005 · Cited by 140
Margolese, H. C., Chouinard, G., Kolivakis, T., Beauclair, L., Miller, R. J., & Annable, L. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505001110 · Cited by 138
Self-citationOn the supersensitivity of dopamine receptors, induced by neuroleptics
Christensen, A. V., Fjalland, B., & Nielsen, I. M. (1976) · Psychopharmacology · doi:10.1007/bf00423298 · Cited by 134
Treatment strategies to prevent relapse and encourage remission.
Kane, J. M. (2007) · PubMed · Cited by 131
Phenothiazine-Induced Decompensation
Putten, T. V. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760070080012 · Cited by 126
Chouinard, G. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00007 · Cited by 124
Self-citationValenti, O., Cifelli, P., Gill, K. M., & Grace, A. A. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2808-11.2011 · Cited by 124
Severe cases of neuroleptic-induced supersensitivity psychosis
Chouinard, G. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90050-2 · Cited by 123
Self-citationBrain dopamine transporter: gender differences and effect of chronic haloperidol
Rivest, R., Falardeau, P., & Paolo, T. D. (1995) · Brain Research · doi:10.1016/0006-8993(95)00611-s · Cited by 123
Less Is More: Antipsychotic Drug Effects Are Greater with Transient Rather Than Continuous Delivery
Samaha, A., Reckless, G. E., Seeman, P. M., Diwan, M., Nóbrega, J. N., & Kapur, S. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.010 · Cited by 121
Self-citationWilmot, C. A., & Szczepanik, A. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)90833-0 · Cited by 119
Post, R. M., Kopanda, R. T., & Black, K. E. (1976) · PubMed · Cited by 118
Graff‐Guerrero, A., Mizrahi, R., Agid, O., Marcon, H., Barsoum, P., Rusjan, P., Wilson, A. A., Zipursky, R. B., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.199 · Cited by 116
Tarazi, F. I., Zhang, K., & Baldessarini, R. J. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29589-6 · Cited by 116
Takeuchi, H., Suzuki, T., Uchida, H., Watanabe, K., & Mimura, M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2011.11.021 · Cited by 115
Striatal dopamine release in schizophrenia comorbid with substance dependence
Thompson, J. L., Urban, N., Slifstein, M., Xu, X., Kegeles, L. S., Girgis, R. R., Beckerman, Y., Harkavy‐Friedman, J., Gil, R. B., & Abi‐Dargham, A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.109 · Cited by 115
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
O’Dell, S. J., LaHoste, G. J., Widmark, C., Shapiro, R. M., Potkin, S. G., & Marshall, J. F. (1990) · Synapse · doi:10.1002/syn.890060205 · Cited by 112
Smith, R. C., & Davis, J. M. (1976) · Life Sciences · doi:10.1016/0024-3205(76)90170-3 · Cited by 111
Iyo, M., Tadokoro, S., Kanahara, N., Hashimoto, T., Niitsu, T., Watanabe, H., & Hashimoto, K. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31828ea95c · Cited by 105
Self-citationCholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal
Shiovitz, T. M., Welke, T. L., Tigel, P. D., Anand, R., Hartman, R. D., Sramek, J. J., Kurtz, N. M., & Cutler, N. R. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.4.591 · Cited by 104
Chouinard, G., Annable, L., Ross‐Chouinard, A., & Mercier, P. (1988) · PubMed · Cited by 102
Self-citationIs schizophrenia a dopamine supersensitivity psychotic reaction?
Seeman, M. V., & Seeman, P. M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.003 · Cited by 100
Cho, D.-I., Zheng, M., Min, C., Ma, L., Kurose, H., Park, J. H., & Kim, K.-M. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0369 · Cited by 98
Schatzberg, A. F., Blier, P., Delgado, P. L., Fava, M., Haddad, P. M., & Shelton, R. C. (2006) · PubMed · Cited by 94
Tadokoro, S., Okamura, N., Sekine, Y., Kanahara, N., Hashimoto, K., & Iyo, M. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr006 · Cited by 92
Ginovart, N., Wilson, A. A., Hussey, D. F., Houle, S., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.116 · Cited by 90
ECT continuation and maintenance in a patient with psychosis and mental disability.
Chouinard, G., Beauclair, L., & Bélanger, M. C. (1998) · PubMed · Cited by 89
Self-citationSupersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal
Ekblom, B., Eriksson, K., & Lindstr�m, L. H. (1984) · Psychopharmacology · doi:10.1007/bf00464798 · Cited by 88
Chronic Hypnotic-Drug Use: Ineffectiveness, Drug-Withdrawal Insomnia, and Dependence
Kales, A. (1974) · JAMA · doi:10.1001/jama.1974.03230180011004 · Cited by 88
Oda, Y., Kanahara, N., & Iyo, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226228 · Cited by 84
Self-citationDopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia
Suzuki, T., Kanahara, N., Yamanaka, H., Takase, M., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.021 · Cited by 81
Self-citationFava, G. A., Bernardi, M., Tomba, E., & Rafanelli, C. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706007462 · Cited by 80
Huang, M., Panos, J., Kwon, S., Oyamada, Y., Rajagopal, L., & Meltzer, H. Y. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12512 · Cited by 79
Ishigooka, J., Nakamura, J., 藤井, 康., Iwata, N., Kishimoto, T., Iyo, M., Uchimura, N., Nishimura, R., & Shimizu, N. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.12.013 · Cited by 75
Self-citationChouinard, V., Pingali, S. M., Chouinard, G., Henderson, D. C., Mallya, S. G., Cypess, A. M., Cohen, B. M., & Öngür, D. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.024 · Cited by 74
Self-citationBeta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases
Houston, M. C., & Hodge, R. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90627-8 · Cited by 72
Kales, A. (1970) · Archives of General Psychiatry · doi:10.1001/archpsyc.1970.01750030019004 · Cited by 68
Effects of stringent criteria on eligibility for clozapine among public mental health clients
Juarez-Reyes, M. G., Shumway, M., Battle, C., Bacchetti, P., Hansen, M. S., & Hargreaves, W. A. (1995) · Psychiatric Services · doi:10.1176/ps.46.8.801 · Cited by 67
Remington, G., Seeman, P., Feingold, A., Mann, S., Shammi, C., & Kapur, S. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05866yel · Cited by 65
Turrone, P., Remington, G. J., Kapur, S., & Nóbrega, J. N. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1259-z · Cited by 64
Li, Z., Ichikawa, J., Huang, M., Prus, A. J., Dai, J., & Meltzer, H. Y. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0170-9 · Cited by 62
(2012) · Europe PMC (PubMed Central) · Cited by 61
Margolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61
Self-citationSCHIZOPHRENIA AS DOPAMINE-DEFICIENCY DISEASE
Chouinard, G., & Jones, B. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91409-5 · Cited by 61
Self-citationRc, S., & Jm, D. (1975) · PubMed · Cited by 61
Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol.
Rangno, R., & Langlois, S. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb01939.x · Cited by 60
(1980) · American Journal of Psychiatry · doi:10.1176/ajp.137.11.1395 · Cited by 59
Why is it so difficult to stop psychiatric drug treatment?
Moncrieff, J. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.03.009 · Cited by 59
Can antipsychotic treatment contribute to drug addiction in schizophrenia?
Samaha, A. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.008 · Cited by 58
Self-citationTardive dyskinesia and antiparkinsonian medication
Chouinard, G., de Montigny, C., & Annable, L. (1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.2.228 · Cited by 58
Self-citationCloos, J.-M., Bocquet, V., Rolland-Portal, I., Koch, P., & Chouinard, G. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000434755 · Cited by 57
Self-citationHuang, N. (1997) · Neurochemistry International · doi:10.1016/s0197-0186(96)00093-9 · Cited by 57
Fallon, P., & Dursun, S. M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109359097 · Cited by 56
Up-regulation of dopamine D2 receptor mRNA in rat striatum by chronic neuroleptic treatment
Rogue, P. J., Hanauer, A., Zwiller, J., Malviya, A. N., & Vincendon, G. (1991) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(91)90092-v · Cited by 56
Kimura, H., Kanahara, N., Komatsu, N., Ishige, M., Muneoka, K., Yoshimura, M., Yamanaka, H., Suzuki, T., Komatsu, H., Sasaki, T., et al. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.02.022 · Cited by 55
Self-citationAse, A. R., Amdiss, F., Hébert, C., Huang, N., van Gelder, N. M., & Reader, T. A. (1999) · Journal of Neural Transmission · doi:10.1007/s007020050142 · Cited by 55
Neuroleptic discontinuation syndromes
Tranter, R., & Healy, D. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200412 · Cited by 54
Takase, M., Kanahara, N., Oda, Y., Kimura, H., Watanabe, H., & Iyo, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115570083 · Cited by 54
Self-citationNew nomenclature for drug-induced movement disorders including tardive dyskinesia.
Chouinard, G. (2004) · PubMed · Cited by 50
Self-citationIntermittent Pimozide versus Fluphenazine Decanoate as Maintenance Therapy in Chronic Schizophrenia
McCreadie, R. G., Dingwall, J. M., Wiles, D. H., et al. (1980) · The British Journal of Psychiatry · doi:10.1192/bjp.137.6.510 · Cited by 50
Is there a limbic system equivalent of tardive dyskinesia?
Davis, K. L., & Rosenberg, G. S. (1979) · PubMed · Cited by 50
Continuous, but not Intermittent, Antipsychotic Drug Delivery Intensifies the Pursuit of Reward Cues
Bédard, A.-M., Maheux, J., Lévesque, D., & Samaha, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.10 · Cited by 49
Self-citationKusumi, I., Takahashi, Y., Suzuki, K., et al. (2000) · Journal of Neural Transmission · doi:10.1007/s007020050024 · Cited by 48
Quetiapine Extended-Release Versus Immediate-Release Formulation
Mamo, D. C., Uchida, H., Vitcu, I., Barsoum, P., Gendron, A., Goldstein, J. M., & Kapur, S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0111 · Cited by 48
Brunelin, J., d’Amato, T., van Os, J., Costes, N., Suaud‐Chagny, M., & Saoud, M. (2010) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2009.10.002 · Cited by 47
Fallon, P., Dursun, S., & Deakin, B. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311431105 · Cited by 47
Isbister, G. K., Murray, L., John, S., Hackett, L. P., Haider, T., OˈMullane, P., Gosselin, S., & Daly, F. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00272.x · Cited by 46
Belaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000341178 · Cited by 45
Self-citationBelaise, C., Gatti, A., Chouinard, V.-A., & Chouinard, G. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000362317 · Cited by 44
Self-citationSupersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients.
Chouinard, G., Annable, L., & Ross‐Chouinard, A. (1986) · PubMed · Cited by 44
Self-citationChouinard, G., Vainer, J. L., Bélanger, M., Turnier, L., Beaudry, P., Roy, J.-Y., & Miller, R. J. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90116-3 · Cited by 43
Self-citationThe Concept of Supersensitivity Psychosis
Kirkpatrick, B. W., Alphs, L. D., & Buchanan, R. W. (1992) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199204000-00009 · Cited by 41
McGarvey, K., Zis, A. P., Brown, E. E., et al. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90385-q · Cited by 40
Fukushiro, D. F., Carvalho, R. C., Ricardo, V. P., Alvarez, J. D. N., Ribeiro, L. T. C., & Frussa‐Filho, R. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.05.004 · Cited by 40
Serotonin Syndrome Associated With Clozapine Withdrawal
Stevenson, E., Schembri, F., Green, D. M., & Burns, J. D. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.95 · Cited by 39
Ichikawa, J., & Meltzer, H. Y. (1992) · Brain Research · doi:10.1016/0006-8993(92)90805-j · Cited by 39
Bédard, A.-M., Maheux, J., Lévesque, D., & Samaha, A. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs077 · Cited by 38
Self-citationSasaki, H., Hashimoto, K., Maeda, Y., Inada, T., Kitao, Y., Fukui, S., & Iyo, M. (1995) · Life Sciences · doi:10.1016/0024-3205(95)00218-u · Cited by 37
Self-citationMaintenance Treatment of Severe Tardive Dyskinesia With Clozapine
Louzã, M. R., & Bassitt, D. P. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000155823.59585.88 · Cited by 37
Chronic neuroleptic treatment and dopamine receptor regulation.
Creese, I., & Sh, S. (1980) · PubMed · Cited by 37
5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity
Charron, A., Hage, C. E., Servonnet, A., & Samaha, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.10.002 · Cited by 36
Self-citationUchida, H., & Suzuki, T. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000065 · Cited by 35
Fukushiro, D. F., Alvarez, J. D. N., Tatsu, J. A. O., de Castro, J. P. M. V., Chinen, C. C., & Frussa‐Filho, R. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.01.025 · Cited by 33
(2006) · PubMed · Cited by 33
Self-citationSanford, M. (2011) · CNS Drugs · doi:10.2165/11207280-000000000-00000 · Cited by 32
Seeman, P. M. (2011) · Synapse · doi:10.1002/syn.20987 · Cited by 32
Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy
GILLIGAN, D. M., Chan, W., Stewart, R., et al. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90651-z · Cited by 32
Meeting everyday challenges: Antipsychotic therapy in the real world
Gorwood, P. A. P. M. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.06.002 · Cited by 32
Montanaro, N., Dall’Olio, R., Gandolfi, O., & Vaccheri, A. (1982) · European Journal of Pharmacology · doi:10.1016/0014-2999(82)90595-7 · Cited by 32
Carvalho, R. C., Fukushiro, D. F., Helfer, D. C., Callegaro‐Filho, D., Trombin, T. F., Zanlorenci, L. H. F., Sanday, L., Silva, R. H., & Frussa‐Filho, R. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00145.x · Cited by 30
Dopamine partial agonist action of (−)OSU6162 is consistent with dopamine hyperactivity in psychosis
Seeman, P. M., & Guan, H. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.016 · Cited by 30
Huang, M., Kwon, S., Oyamada, Y., Rajagopal, L., Miyauchi, M., & Meltzer, H. Y. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.09.011 · Cited by 29
Marin, C., & Chase, T. N. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90448-q · Cited by 28
Dopamine D2Highreceptors moderately elevated by bifeprunox and aripiprazole
Seeman, P. M. (2008) · Synapse · doi:10.1002/syn.20557 · Cited by 28
Is Neuroleptic Dysphoria a Variant of Drug-Induced Extrapyramidal Side Effects?
Voruganti, L. P., & Awad, A. G. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900502 · Cited by 28
Sasaki, H., Hashimoto, K., Inada, T., Fukui, S., & Iyo, M. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00278-s · Cited by 26
Self-citationEricson, H., Radesäter, A. ‐., Servin, E., et al. (1996) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.1996.tb00009.x · Cited by 26
A Rating Scale for Psychotic Symptoms (RSPS)
Chouinard, G., & Miller, R. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00012-2 · Cited by 26
Self-citationKimura, H., Kanahara, N., Sasaki, T., Komatsu, N., Ishige, M., Muneoka, K., Ino, H., Yoshimura, K., Yamanaka, H., Suzuki, T., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116655978 · Cited by 26
Self-citationEfficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia
Nakata, Y., Kanahara, N., Kimura, H., Watanabe, H., & Iyo, M. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000160 · Cited by 26
Self-citationInoue, T., Osada, K., Tagawa, M., et al. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.06.005 · Cited by 25
Severson, J. A., Robinson, H. E., & Simpson, G. M. (1984) · Psychopharmacology · doi:10.1007/bf00432038 · Cited by 25
Evidence of Brain Dopamine Deficiency in Schizophrenia
Chouinard, G., & Jones, B. (1979) · The Canadian Journal of Psychiatry · doi:10.1177/070674377902400710 · Cited by 23
Self-citationHu, W., Fang, Q., Xu, Z., Yan, H., He, P., Zhong, K. L., Fan, Y., Yang, Y., Zhang, X., Zhang, C., et al. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00356.x · Cited by 23
Management of Drug and Alcohol Withdrawal
Huitink, J. M., & Buitelaar, D. R. (2003) · New England Journal of Medicine · doi:10.1056/nejm200307243490420 · Cited by 22
Hage, C. E., Bédard, A.-M., & Samaha, A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.03.012 · Cited by 22
Self-citationPrevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule
Rangno, R. E., Nattel, S., & Lutterodt, A. (1982) · The American Journal of Cardiology · doi:10.1016/0002-9149(82)91965-8 · Cited by 21
Oda, Y., Tadokoro, S., Takase, M., Kanahara, N., Watanabe, H., Shirayama, Y., Hashimoto, K., & Iyo, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115593903 · Cited by 20
Self-citationElectroconvulsive shock prevents dopamine receptor supersensitivity
Lerer, B., Jabotinsky-Rubin, K., Bannet, J., Ebstein, R. P., & Belmaker, R. H. (1982) · European Journal of Pharmacology · doi:10.1016/0014-2999(82)90188-1 · Cited by 20
Early onset of tardive dyskinesia: case report
(1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.10.1323 · Cited by 20
Self-citationEffects of fluperlapine on dopaminergic systems in rat brain
Bürki, H. R. (1986) · Psychopharmacology · doi:10.1007/bf00175194 · Cited by 19
Kristensen, D., Hageman, I., Bauer, J., et al. (2013) · Journal of Ect · doi:10.1097/yct.0b013e31828b34f6 · Cited by 19
Lee, L. H. N., Choi, C., Collier, A. C., Barr, A. M., Honer, W. G., & Procyshyn, R. M. (2015) · CNS Drugs · doi:10.1007/s40263-015-0295-2 · Cited by 19
Tachibana, M., Niitsu, T., Watanabe, M., Hashimoto, T., Kanahara, N., Ishikawa, M., & Iyo, M. (2016) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2016.08.014 · Cited by 18
Self-citationFALLON, P. (2009) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/j.1365-2850.2009.01451.x · Cited by 16
Aripiprazole: Effectiveness and safety under naturalistic conditions.
Lorenzo, R. D., Amoretti, A., Forghieri, M., Fiorini, F., Genedani, S., & Rigatelli, M. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.6.569 · Cited by 16
Chouinard, G., Boisvert, D., & Bradwejn, J. (1982) · PubMed Central · Cited by 15
Self-citationLong-Term Lamotrigine Adjunctive to Antipsychotic Monotherapy in Schizophrenia: Further Evidence
Kolivakis, T., Beauclair, L., Margolese, H. C., & Chouinard, G. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900411 · Cited by 15
Self-citation
Research works printed but not linked: 1
- 10.2165/1120086-000000000-00000 · doi:10.2165/1120086-000000000-00000
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
“…D2 receptors which has been held to be potentially responsible for breakthrough psychotic relapse in people with schizophrenia on maintenance antipsychotic medication as well as rebound psychosis after abruptly stopping treatment (Chouinard, 1991; Chouinard et al., 2017; Kimura et al., 2016).”
BackgroundPotkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359
“2a).(33,37) In turn, increases in antipsychotic medication doses to control breakthrough symptoms are thought to lead to further increases in DRD2 density, resulting in increased dopamine supersensitivity, and consequently, the reemergence of symptoms.”
BackgroundResultInfluentialAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Self-citationFava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide
Montastruc, F., Nie, R., Loo, S., Rej, S., Dell’Aniello, S., Micallef, J., Suissa, S., & Renoux, C. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4149 · Cited by 179
Metadata
- Authors
- Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M.
- Affiliations
- Hôpital Saint-Antoine (FR)
- McLean Hospital (US)
- Chiba University (JP)
- ORCID
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 86
- Issue
- 4
- Pages
- 189-219
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2701376032
- Cited by
- 270
- References
- 221
- Citations by year
- 2026: 29 · 2025: 19 · 2024: 32 · 2023: 36 · 2022: 29 · 2021: 39 · 2020: 29 · 2019: 37 · 2018: 17 · 2017: 3
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (17K10266)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- dopamine receptor supersensitivity, tardive dyskinesia, treatment-resistant schizophrenia, psychotic relapse, atypical antipsychotics, long-acting injectable antipsychotics, prolactin, drug-induced movement disorders
- MeSH terms
- Brain, Dopamine, Humans, Psychoses, Substance-Induced, Antipsychotic Agents, Receptors, Dopamine D2, Dopamine D2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.